Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P15088 (
mast cell
)
14,925
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mast cells have been implicated in a number of diseases involving chronic inflammation including asthma, rheumatoid arthritis, and inflammatory bowel diseases. They are a potent source of several cytokines, including IL-6 and
TNF-alpha
. Freshly isolated rat peritoneal mast cells will produce IL-6 in response to anti-IgE, LPS, PGE1, or PGE2; however, the mechanisms by which such cytokine production is regulated are poorly understood. IL-10 is recognized as an important immunoregulatory cytokine with effects on T cell development and the production of inflammatory cytokines. IL-10 has previously been described to enhance
mast cell
development in the context of IL-3 and IL-4. In the current study, we have examined the ability of IL-10 to modulate rat peritoneal
mast cell
IL-6 and
TNF-alpha
production in response to a variety of stimuli. We have observed that recombinant murine IL-10 can inhibit the production of both IL-6 and
TNF-alpha
by mast cells without altering the degree of histamine release in response to anti-IgE. Concentrations of IL-10 as low as 0.2 ng/ml were sufficient to inhibit IL-6 production by LPS- or anti-IgE-activated cells significantly. IL-10 also inhibited PGE1- and PGE2-induced IL-6 production. The relative potency of IL-10 as an inhibitor of
mast cell
IL-6 production was highly dependent upon the stimulus used, with a 10-fold difference in the IC50 for LPS- or anti-IgE-activated cells (0.21 ng/ml) and cells activated with a combination of LPS and PGE2 (2.29 ng/ml). This suggests that prostanoids may limit the ability of IL-10 to modulate
mast cell
IL-6 production in the context of inflammation. These data have important implications for the regulation of
mast cell
IL-6 in inflammatory diseases involving prostanoid production and the effects of treatment with cyclooxygenase inhibitors. Our results also demonstrate a dual role for IL-10 on mast cells as a growth factor and inhibitor of cytokine production.
...
PMID:Interleukin (IL)-10 inhibits long-term IL-6 production but not preformed mediator release from rat peritoneal mast cells. 861 37
Mast cells activated via high-affinity receptors for IgE can produce a variety of multifunctional cytokines, including
TNF-alpha
, which is thought to be involved in the pathophysiology of allergic diseases and other inflammatory disorders. We investigated the regulation of Fc Fc epsilon RI-dependent
TNF-alpha
production by mouse mast cells using dexamethasone and pentoxifylline, pharmacological agents which are known to suppress
TNF-alpha
production by macrophages. We now report that either dexamethasone or pentoxifylline can inhibit IgE-dependent mouse
mast cell
production of
TNF-alpha
; however, the major site of action of these agents was different. Pentoxifylline inhibited
mast cell
TNF-alpha
gene transcription, while dexamethasone inhibited
TNF-alpha
production predominantly by a post-transcriptional mechanism. These results demonstrate that the synthesis of
mast cell
TNF-alpha
can be regulated pharmacologically at either the transcriptional or the translational level and that pentoxifylline and dexamethasone, two agents that are used to treat inflammatory disorders, can modulate
mast cell
TNF-alpha
production at different points in the synthetic pathway of this cytokine.
...
PMID:The regulation of tumor necrosis factor-alpha production in murine mast cells: pentoxifylline or dexamethasone inhibits IgE-dependent production of TNF-alpha by distinct mechanisms. 866 Aug 49
Ag stimulation of mast cells via the IgE receptor (Fc epsilon RI) elicits production and release of numerous cytokines. This activation of Fc epsilon RI initiates various tyrosine kinase-dependent signaling cascades, which ultimately result in the de novo synthesis of cytokines. To date, no heterotrimeric G proteins have been implicated in this process. Here we report that the alpha subunit of the heterotrimeric G protein, Gz, can regulate production of the cytokine,
TNF-alpha
. The alpha subunit was overexpressed in a cultured
mast cell
line (RBL-2H3) known to contain G alpha z. In stimulated cells, overexpression of G alpha z significantly enhanced the production of
TNF-alpha
. This effect of G alpha z appeared to be restricted in that constitutive synthesis of the cytokine, TGF-beta, and Ag-stimulation of the phosphoinositide-dependent secretory pathway were not significantly affected. Thus, G alpha z, a heterotrimeric G protein, appeared to modulate the stimulatory pathways for induction of
TNF-alpha
synthesis in RBL-2H3 cells.
...
PMID:Enhancement of TNF-alpha synthesis by overexpression of G alpha z in a mast cell line. 875 48
Immunoglobulin E (IgE) that specifically binds to antigens present on carcinoma cells may represent a useful tool to combat carcinomas. Induction of an inflammatory response at the tumor site by tumor-specific IgE may result in reduced tumor growth and tumor regression. Local mast cells may be activated to release
TNF-alpha
and other mediators that attract inflammatory cells, such as eosinophils and macrophages, to the tumor site. It may even be expected that eosinophils perform IgE-mediated lysis of tumor cells. The G250 IgE binds an antigen present on renal cell carcinoma. Mast cells were assayed for activation by G250 IgE in vitro in the presence of G250-positive tumor cells, by determination of the release of
TNF-alpha
and histamine. In parallel, G250 IgG1, IgG2a, and IgG2b, bound to tumor cells, were tested for their ability to activate mast cells. Tumor-specific IgE was capable of activating mast cells in the presence of tumor cells. This activation was specific and required the presence of the antigen on the tumor cell surface and recognition of the tumor cell by the IgE. G250 IgE mediated
mast cell
activation when present in the medium as well as being preloaded on either tumor cells or mast cells. Preincubation of mast cells with irrelevant IgE did not block specific G250 IgE-mediated
mast cell
activation. Upon activation, mast cells released histamine and
TNF-alpha
, as was detected in cytotoxicity assays with
TNF-alpha
-sensitive target cells (WEHI). G250 IgG2a also induced efficient
mast cell
activation, comparable to the effect of G250 IgE. Mast cells can be triggered to release mediators such as
TNF-alpha
by IgE in the presence of tumor cells expressing specific antigen. Whether
mast cell
activation contributes to antitumor effects observed during antibody-based immunotherapy of tumors deserves further investigation.
...
PMID:Target-specific activation of mast cells by immunoglobulin E reactive with a renal cell carcinoma-associated antigen. 878 Jan 64
Mast cells cultured from bone marrow of BALB/c and SJL/J inbred strains of mice using IL-3 showed distinct patterns of growth and marked differences in their content of
TNF-alpha
and histamine. Mast cells derived from SJL/J mice grew and matured at a faster rate than those from BALB/c bone marrow. SJL/J mast cells were found to contain more than twice the amount of histamine and
TNF-alpha
in their granules than BALB/c-derived cells. In addition, when triggered by anti-DNP IgE antibody and specific antigen (DNP-albumin), mast cells derived from SJL/J mice released more histamine and
TNF-alpha
than mast cells derived from BALB/c mice. These results confirm previous observations regarding a genetic basis for mouse strain differences in
mast cell
growth rates, and extend previous observations to document differences in
mast cell
mediator contents. These results are consistent with the concept that genetically controlled differences in the numbers of central nervous system (CNS)-associated mast cells and their vasogenic mediators may play an important role in modulating oedema and inflammation in CNS trauma and diseases in mice.
...
PMID:Mast cell-derived histamine and tumour necrosis factor: differences between SJL/J and BALB/c inbred strains of mice. 879 21
While it was recently shown that activation of dendritic cells (DC) results in the production of a number of cytokines, the signal pathways and transcription factors involved in this process have not been described. To address this issue we compared the events resulting in the activation of the human
TNF-alpha
promoter occurring in the fetal dendritic cell line 18 (DC18) with those in the well-characterized murine
mast cell
line CPII. As stimuli we employed the protein kinase C inducer, PMA, and the Ca2+ ionophore, ionomycin, both of which are known to activate a large variety of intracellular signaling pathways. In the DC18 cells, PMA alone induces the
TNF-alpha
promoter in a macrolide-insensitive manner. In contrast, in the
mast cell
line CPII, both stimuli (PMA plus ionomycin) are necessary for promoter activation which, in addition, is sensitive to immunosuppressive drugs. Mapping of the
TNF-alpha
promoter showed that in both cell types the so-called kappa factor binding site is the crucial promoter element for the induction. We show that in DC18 cells, this sequence is bound to and controlled by NF-kappaB proteins p50 (NF-kappaB1) and p65 (ReIA), whereas in CPII mast cells, NF-AT and AN factors are the predominant proteins that bind to and control the kappaB element of the
TNF-alpha
promoter. These and further experimental data indicate that in DC, NF-kappaB factors play a predominant role in the activation of the
TNF-alpha
promoter and, possibly, of other cytokine promoters.
...
PMID:Induction of the TNF-alpha promoter in the murine dendritic cell line 18 and the murine mast cell line CPII is differently regulated. 880 69
We found that production and release of two functionally antagonistic cytokines, TGF-beta and
TNF-alpha
, were regulated differently in the
mast cell
, T cell, and macrophage cell lines RBL-2H3, MLA-144, and U-937, respectively. TGF-beta was produced and released constitutively in all three cell lines. When, however, the cell lines were stimulated with Ag, LPS, or calcium ionophore plus PMA, acceleration of release and some additional production of TGF-beta were apparent. In contrast,
TNF-alpha
was produced and released only when these lines were stimulated. Although neither the glucocorticoid, dexamethasone, nor the protein kinase C inhibitor, Ro31-7549, suppressed constitutive production or release of TGF-beta, these agents inhibited
TNF-alpha
production and the inducible component of TGF-beta production noted above. The release of these cytokines, whether constitutive or inducible, was dependent on Golgi-processing as indicated by inhibition with brefeldin A. Therefore, although both types of cytokines were processed by Golgi, only
TNF-alpha
and the inducible component of TGF-beta production were protein kinase C or steroid-regulated processes. These findings suggested that constitutive and inducible pathways exist for production and release of cytokines and that the inducible pathways can be selectively suppressed by pharmacologic agents.
...
PMID:Constitutive and inducible mechanisms for synthesis and release of cytokines in immune cell lines. 889 43
Long-term culture of mouse spleen cells in IL-3-conditioned medium induced a stable
mast cell
line. This
mast cell
line (MCL) which could not be cloned expressed NC-1.1, a receptor on cells which mediate natural cytotoxicity (NC), and CD32/CD16 but no markers of T cells, B cells, macrophages, or NK cells. The MCL cells were large and granular, with abundant cytoplasm and >90% stained with Alcian blue, a
mast cell
-specific stain. Probing total RNA with cDNA encoding a
mast cell
-specific proteinase mMCP-5 identified the approximately 1-kb mMCP-5 transcript which was confirmed at the protein level. MCL cells mediated very high NC against WEHI-164 which increased with time in culture and which was blocked by anti-NC-1.1 but not by anti-
TNF-alpha
. When incubated with WEHI-164 tumor cells, MCL cells showed transient induction of
TNF-alpha
mRNA, but no detectable surface protein. Thus long-term culture of murine spleen cells in IL-3 induces mast cells which express the NC-1.1 receptor of cells which mediate NC, and utilize a cytotoxic effector mechanism which is not
TNF-alpha
.
...
PMID:An IL-3-induced splenic NC-1.1+ mast cell line mediates natural cytotoxicity independent of TNF-alpha. 895 14
Pathologic fibroblast proliferation or tissue fibrosis develops in certain chronic allergic diseases and in a wide array of other inflammatory disorders in which
mast cell
activation is also a prominent feature. In this study we investigated a number of potential mechanisms by which IgE-dependent activation of mouse mast cells might influence the proliferation of mouse fibroblasts in vitro. We found that supernatants from in vitro-derived mast cells that had been activated by IgE and specific antigen (but not those from quiescent mast cells) promoted the proliferation of mouse embryonic skin or 3T3 fibroblasts, and we showed that this effect was detectable in the absence of fetal calf serum. We analyzed the kinetics with which the fibroblast-proliferative activity was secreted from bone marrow-derived cultured mast cells and found that it was released both rapidly (i.e., in 30 minutes or less) and for a more prolonged period (i.e., for more than 2 hours) after IgE-dependent
mast cell
activation. We then measured the levels at which the mast cells produce a number of cytokines that are known to affect fibroblasts (IL-1, IL-6, transforming growth factor-beta 1 [TGF-beta 1], and tumor necrosis factor-alpha [
TNF-alpha
]) and assessed their relative effects, as recombinant cytokines, on fibroblast proliferation. Our mast cells secreted high levels of TGF-beta 1 and
TNF-alpha
, intermediate amounts of IL-6, and low levels of IL-1. We titrated the fibroproliferative effects of each of these cytokines and determined that at a dose of 50 pg/ml their rank order of activity was TGF-beta 1 >
TNF-alpha
> IL-1 > IL-6, with all but IL-6 having significant effects. The ability of supernatants from activated bone marrow-derived cultured mast cells to promote fibroblast proliferation was partially diminished by absorption with neutralizing antibodies against either
TNF-alpha
or TGF-beta 1, and absorption of the supernatants with a combination of antibodies against
TNF-alpha
and TGF-beta 1 reduced their ability to induce fibroblast proliferation by approximately 50% (p < or = 0.001, n = 5). These findings show that IgE-dependent activation of mouse mast cells can result in the release of mediators that promote fibroblast proliferation in the absence of any other cell type and suggest that
mast cell
-derived
TNF-alpha
and TGF-beta 1 contribute substantially to this effect. They also suggest that these cytokines exert their effects through synergistic interactions with other
mast cell
mediators.
...
PMID:Promotion of mouse fibroblast proliferation by IgE-dependent activation of mouse mast cells: role for mast cell tumor necrosis factor-alpha and transforming growth factor-beta 1. 900 19
The present study unequivocally demonstrated the expression of CD28 on murine bone marrow-derived cultured mast cells and a
mast cell
line, MCP-5. Stimulation of surface CD28 molecules on mast cells with anti-CD28 mAbs induced tyrosine phosphorylation of cellular proteins, including several protein tyrosine kinases and their substrates, such as Itk/Emt (Emt), Btk, Syk, c-Cbl, Shc, and Vav. CD28-stimulated tyrosine phosphorylation was followed by a rebound hypophosphorylation. Interestingly, CD28 stimulation alone elicited a low level secretion of
TNF-alpha
. On the other hand, cross-linking of the high affinity IgE receptor (Fc epsilon RI) on mast cells induces a set of activation events, i.e., degranulation, secretion of eicosanoids, secretion of cytokines, and DNA synthesis. Concurrent stimulation of mast cells through CD28 enhanced Fc epsilon RI-induced
TNF-alpha
secretion in a dose-dependent manner. Together, the present data suggest a role for CD28-mediated costimulation of mast cells in the initiation and progression of allergic responses and other diseases.
...
PMID:Increased secretion of TNF-alpha by costimulation of mast cells via CD28 and Fc epsilon RI. 903 88
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>